Pluri Inc. Stock

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-04-15 pm EDT 5-day change 1st Jan Change
5.67 USD -1.39% Intraday chart for Pluri Inc. +1.25% +22.30%
Sales 2022 234K Sales 2023 287K Capitalization 32.98M
Net income 2022 -41M Net income 2023 -28M EV / Sales 2022 58 x
Net cash position 2022 26.21M Net cash position 2023 10.27M EV / Sales 2023 79.1 x
P/E ratio 2022
-0.96 x
P/E ratio 2023
-1.04 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 75.38%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Pluri Receives US Patent for Immune Cell Expansion MT
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology CI
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing CI
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation CI
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis CI
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division CI
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO CI
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation CI
More news
1 day-1.39%
1 week+1.25%
Current month-12.07%
1 month-28.93%
3 months+26.56%
6 months+33.73%
Current year+22.30%
More quotes
1 week
5.25
Extreme 5.2501
6.26
1 month
4.50
Extreme 4.5
8.40
Current year
4.16
Extreme 4.16
8.48
1 year
3.45
Extreme 3.4488
8.56
3 years
3.45
Extreme 3.4488
40.48
5 years
3.45
Extreme 3.4488
106.32
10 years
3.45
Extreme 3.4488
304.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 06-10-31
Director of Finance/CFO 40 13-04-30
Chairman 70 05-09-25
Members of the board TitleAgeSince
Director/Board Member 72 21-07-14
Director/Board Member 55 23-07-10
Chairman 70 05-09-25
More insiders
Date Price Change Volume
24-04-15 5.67 -1.39% 13,179
24-04-12 5.75 -0.86% 23,110
24-04-11 5.8 -2.68% 58,395
24-04-10 5.96 +4.93% 44,627
24-04-09 5.68 +1.43% 38,387

Delayed Quote Nasdaq, April 15, 2024 at 04:30 pm EDT

More quotes
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
More about the company